Clinical TrialsEnrollment is ongoing in the initial dose escalation cohort in patients 6 to 31 months, and ALSEN remains on track for completion of dosing in the first dose cohort by YE24.
Financial PerformanceSensorion released its 1H24 results, ending the semester with a cash position of €87.3m, providing financial visibility until end-2025.
Regulatory ProgressALSEN plans to request a pre-IND meeting with the FDA by YE24 for inclusion of US sites in the potentially registrational dose expansion portion of the study.